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Abstract
Under diabetes mellitus, the administration of Galega officinalis promotes res-
toration of leukocyte precursors’ bone marrow pool and normalizes their prolifera-
tive activity. This plant protects the functional state of leukocytes by modulating 
actin cytoskeleton formation and through quantitative redistribution of leukocyte 
membrane glycoconjugates. Galega officinalis prevents the development of diabetes-
associated oxidative stress which results in antiapoptotic activity. The normalization 
of leukocytes’ proliferative and functional capacity by Galega officinalis, along with 
its antiapoptotic and hypoglycemic effects, can improve the course of the disease 
and may prevent the development of complications of diabetes.
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1. Introduction
Diabetes mellitus belongs to a group of metabolic diseases accompanied by 
chronic inflammation and attenuation of the immune response, which subsequently 
contributes to the development of a number of complications [1]. Cells that are 
most affected by glycemic status and insulin level are leukocytes, which play major 
roles in inflammation and immune responses [2]. Constant high glucose levels result 
in the formation of cytotoxic compounds, leading to lower viability of peripheral 
blood leukocytes. This is mediated by enhanced reactive species production, 
activation of mitogen-activated protein kinase (MAPK) pathway, high levels of pro-
inflammatory and poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) 
transcription factors, as well as inactivation of pro-survival pathways which alto-
gether leads to increased apoptosis rate. The alterations in these molecular pathways 
are usually associated with increased leukocyte mobilization, which causes changes 
in their morphology and functional state [1, 3].
The multitude of diabetes mellitus complications creates the need for drugs with 
a wide spectrum of action, which would not only provide effective reduction of 
blood glucose but would also exhibit cytoprotective properties. The most commonly 
used anti-diabetes drug globally is metformin. Metformin shows a pleiotropic effect 
mediated by its hypoglycemic function, as well as inhibitory effect on oxidative 
stress and inflammation.
In many cases medicinal plants can be safe and effective alternatives to synthetic 
compounds in disease management, since they possess a unique composition of 
biologically active substances [4].
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Galega officinalis (Galega, goat’s rue, French lilac) is a promising plant that can 
be used for treatment of a wide range of inflammatory diseases, including diabetes 
mellitus. G. officinalis is well-known for its hypoglycemic action, and it has been 
long used as part of a plant mixture for treatment of diabetes mellitus [5]. For a long 
time, the antidiabetic effect of G. officinalis was associated with high content of 
alkaloid galegine, which is one of the main components of this plant’s leaves. In fact, 
metformin, discussed above, is a synthetic form of galegine, which was originally 
used to treat diabetes mellitus type 2 [5]. The toxicity of G. officinalis’ alkaloids 
decreased its attractiveness as a hypoglycemic drug. However, it was found that 
even the non-alkaloid extract has a hypoglycemic effect and is potentially nontoxic 
[6, 7]. Based on such historical use and a large number of recent scientific studies, 
G. officinalis is a source of potent biologically active substances for the prevention 
and treatment of diabetes mellitus [8].
2. Effects of metformin on the immune system
Metformin (N,N-dimethylbiguanide) is an oral antihyperglycemic agent, which 
from a chemical point of view is a synthetic derivative of guanidine. The hypoglyce-
mic effect of this drug is realized through the inhibition of hepatic glucose produc-
tion, reducing intestinal glucose absorption and improving glucose uptake and 
utilization by peripheral tissues. Recent research has shed light on the pleiotropic 
effect of metformin, ranging from hypoglycemic function to cardio- and nephro-
protection, as well as inhibitory effects on oxidative stress and inflammation [9–11].
The scientific data concerning the influence of metformin on the immune sys-
tem is controversial, and its effect strongly depends on the pathology in which it is 
used. For example, metformin enhances antitumor immunity, but in other contexts, 
it can act as an anti-inflammatory or immunosuppressive agent [8]. Metformin can 
suppress senescence- and cancer-related inflammation. The majority of experi-
mental data indicates that metformin modulates leukocytes’ functional activity 
by activating 5′ adenosine monophosphate-activated protein kinase (AMPK). 
Metformin can activate AMPK in multiple cell populations, including macrophages 
and neutrophils [12, 13]. It has also been demonstrated that metformin inhibits 
innate immune response to fungal infection in an AMPK-dependent manner and 
lessens central nervous system inflammation [14].
Considering the significant modulating effect of metformin on the immune 
system, it is unsurprising that it has a strong effect on immunocompetent blood 
cells, which we discuss below.
2.1 Metformin influence on defective hematopoiesis
Studies conducted on Fanconi anemia mice showed the unique property of 
metformin to improve hematopoiesis by restoring hematopoietic stem cell (HSC) 
numbers. It also delays tumor formation, presumably via reduction of DNA damage 
induced by aldehydes [15]. An important part of metformin protective effect may 
be conferred by aldehyde detoxification. Other mechanisms by which metformin 
may act to protect the cell’s DNA are reducing the activity of mitochondrial complex 
1 activity, thus potentially reducing oxidative DNA damage. It is also possible that 
metformin can switch the metabolic balance between oxidative phosphorylation 
and anaerobic glycolysis and downregulate inflammatory pathways which are 
thought to contribute to bone marrow failure [15]. Another study demonstrates 
that metformin treatment significantly inhibited the total-body irradiation-induced 
increase in the levels of DNA double-strand breaks and reactive oxygen species 
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(ROS) by attenuation of NOX4 expression in HSCs. Furthermore, metformin 
modulates the expression of antioxidant enzymes in HSCs [16].
2.2 Influence of metformin on functional state of leukocytes
Many diabetic patients who receive metformin show significantly reduced 
neutrophil-to-lymphocyte ratio [9]. Metformin is able to reduce hyperneutrophilia 
in girls with hyperinsulinemic hyperandrogenism and improves white blood cell 
count in women with polycystic ovary syndrome, two conditions characterized by 
a pronounced systemic inflammatory state [17]. Metformin increased the number 
of CD8-positive tumor-infiltrating lymphocytes. Normalizing effect of metformin 
on the number of immunocompetent cells is associated with its ability to upregulate 
AMPK and as a consequence of altering energy metabolism in the cell [14].
Apart from metformin influence on immunocompetent cell number, this drug 
also can modulate their functional activity. As expected for an AMPK activator, 
metformin enhances cell mobility and phagocytosis, in particular in macrophages 
that show enhanced uptake of bacteria, synthetic beads, or apoptotic cells. The 
effects of AMPK activation may be due to its ability to increase availability of cell 
surface receptors, including αM integrin or Fc receptors or due to mechanisms that 
involve suppression of TLR4-associated signaling pathways. Metformin by activat-
ing AMPK regulates the process of inflammation resolution—efferocytosis and 
enhanced uptake of bacteria by phagocytic cells [12, 13].
Additionally, in patients with prediabetes, metformin treatment reduces the 
concentration of neutrophil extracellular trap (NET) components independently 
from glycemic control [14].
The normalization of phagocytosis processes and NETosis under metformin 
administration could suggest an effect of this drug on neutrophil activation. 
Indeed, metformin attenuates neutrophil activation via inhibition of mitochondrial 
respiratory complex I, potentially through intracellular H2O2-mediated inhibition of 
IκB-α degradation and thus prevention of NF-κB activation [18].
Immune system modulation by metformin can be realized not only by its 
direct influence on the immunocompetent cells but also by its ability to regulate 
chemokine level. Metformin causes a decrease in inflammatory markers in plasma, 
including soluble intercellular adhesion molecule, vascular cell adhesion mol-
ecule-1, macrophage migration inhibitory factor, C-reactive protein, IL-6, and IL-8. 
The anti-inflammatory action of metformin is realized by suppressing Akt, Erk1/2, 
and NF-B translocation. Such changes lead to blocking of pro-inflammatory signal 
transduction via the phosphoinositide 3 kinase pathway [19].
Immunosuppressive effect of metformin can be mediated by its ability to 
inhibit the expression of pro-inflammatory mediators (IFN-, TNF-, IL-1, IL-6, 
IL-17, iNOS, MMP9, and RANTES) and infiltration of immune cells, which was 
blocked by reducing the expression of CAMs (ICAM, VCAM, and E-selectin) on 
vascular cells [20, 21].
2.3 Effects of metformin on oxidative stress
Oxidative stress is the leading cause of microvascular and cardiovascular 
diabetes complications [22]. Disruption of glucose metabolism causes mitochon-
drial superoxide overproduction in cells. An increased amount of superoxide leads 
to overactivity of polyol and hexosamine pathways, increased formation of AGEs 
(advanced glycation end products) and its receptors, and activation of protein 
kinase C isoforms. Altogether, this leads to the development of complications of 
diabetes. Simultaneously endothelial nitric oxide synthase is inactivated. Changes 
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in the activity of these signaling pathways result in increased intracellular ROS and 
activation of pro-inflammatory pathways [22].
Considering such intimate link between diabetes and oxidative stress, anti-
diabetes treatments should not only reduce blood sugar but should also possess 
strong antioxidant properties. Metformin satisfies both criteria; as in addition to a 
hypoglycemic effect, it improves the immunological parameters of patients, pre-
sumably through its antioxidant properties [23]. In aortic endothelial cells, metfor-
min has been shown to inhibit high glucose-dependent ROS overproduction, which 
was mediated by a reduction in NADPH oxidase activity and an inhibition of the 
respiratory chain complex 1. Another possible mechanism of metformin antioxidant 
properties is its ability to activate AMPK with the ensuing induction of manganese 
superoxide dismutase and expression of the antioxidant thioredoxin and endothelial 
NO synthase (eNOS). Additionally, metformin is able to reduce AGEs synthesis 
and the expression of their specific cell receptor called RAGE in endothelial cells 
[16, 23]. In addition to the abovementioned indirect mechanisms of modulation of 
superoxide anion intracellular production, it was found that metformin can directly 
scavenge ROS, in particular •OH but not O2
• [16].
While leukocytes actively participate in ROS generation, they are highly sensi-
tive to ROS-mediated oxidative damage. Metformin was demonstrated to have a 
protective effect against oxidative stress in immunocompetent cells [24].
Furthermore, metformin modulates the function of fMLP-activated polymorpho-
nuclear neutrophils that quench the products of oxidative burst. Researchers hypoth-
esized that metformin may recognize specific cell membrane sites, thereby inducing 
intracellular signal transduction resulting in changes in NADPH oxidase activity or in 
other sources of intracellular ROS [25]. Furthermore, metformin-induced decrease in 
ROS levels led to a partial inhibition of lipid peroxidation in lymphocytes [26].
2.4 A protective role of metformin against apoptosis
Most chronic diseases, including diabetes mellitus, are accompanied by oxida-
tive stress, which may result in apoptosis of different types of cells [27]. Metformin 
has been shown to have protective role on apoptosis. The inhibition of apoptosis 
by metformin has been described in many cell types and under various conditions. 
There may be several mechanisms of apoptosis prevention. Firstly, metformin pos-
sesses good radical scavenging activity. Secondly, metformin can regulate caspase 
levels and induce xenobiotic phase II enzymes [28].
A number of authors have concluded that metformin exerts a neuroprotective 
effect by decreasing mitochondria-dependent apoptosis. This is achieved through 
the inhibition of permeability transition pore opening, blocking the release of cyto-
chrome c and preventing subsequent cell death [29]. A protective role of metformin 
against programmed cell death is likely mediated by maintaining mitochondria 
integrity and reducing Ca2+. This drug also lowers the expression of caspase-3, 
cytochrome c, and cleaved caspase-9 and reduces fragmentation of PARP-1 while 
increasing the expression of Bcl-2 [29]. A similar protective effect of metformin has 
been described for primary rat hepatocytes. Metformin may protect against apop-
tosis by induction of menadione-induced heme oxygenase-1 and bcl-xl expression 
and the reduction of c-Jun N-terminal kinase activation [30, 31].
Given the ability of metformin to inhibit apoptosis of different cells in a variety 
of pathologies, it is possible to assume that it has a similar effect on immunocom-
petent blood cells. Indeed, it was shown that metformin markedly decreased the 
percentage of apoptotic cells in bone marrow cells of rats [32]. It also reduces the 
activation of macrophages and inhibits the expression of COX-2 and caspase-3, 
thereby attenuating inflammatory responses and apoptosis [33].
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Treatment with metformin reduces the amount of oxidant-induced DNA dam-
age in lymphocytes. It was shown that pharmacological concentration (50 μM) of 
metformin could protect against prooxidant stimulus-induced DNA damage at early 
but not late stages. Thus, metformin likely exerts an antiapoptotic effect by reduc-
ing caspase-3 and caspase-8 activities [28].
3.  Effects of Galega officinalis L. on immunocompetent cells under 
diabetes mellitus
Galega officinalis (goat’s rue) is a toxic leguminous plant originated in the Eastern 
Mediterranean and Black Sea regions but now has been spread in southeastern parts 
of Europe and the Middle East. In the medieval period, this plant was traditionally 
used for the treatment of diabetes [5, 34]. G. officinalis contains a large number of 
secondary metabolites with pronounced biological properties, among which are 
alkaloids, saponins, flavonoids, tannins, fatty acids, and phytoestrogens [35].
3.1  Component composition and hypoglycemic effect of non-alkaloid 
extract of Galega officinalis
The non-alkaloid extract of G. officinalis can be obtained by a two-step extrac-
tion [6, 7]. In the first stage, the biologically active substances are obtained by plant 
material infusion in 96 % ethanol. After alcohol evaporation, equal volumes of 
water and chloroform are added to the residue. The obtained chloroform fraction 
should be evaporated to obtain the solid residue, which is then dissolved in water 
to form an emulsion. The latter is not stable and eventually forms a precipitate. The 
stability of emulsions is very important; their stratification affects the accuracy of 
active substance content measurement. To solve this problem, the biocomplex PS 
(surface-active products of Pseudomonas sp. PS-17 biosynthesis) can be used [7]. 
Using gas chromatography/mass spectrometry method, it was established that the 
biocomplex PS consists of methyl ester of decenoic acid and dodecenoic acid. These 
surfactants were added to the initial mixture obtained by the addition of water 
to non-alkaloid fraction of G. officinalis. Such extraction and stabilization yield a 
stable water emulsion without toxic alkaloids [6, 36].
Crucially, such non-alkaloid fraction of G. officinalis extract exhibited a hypo-
glycemic effect in streptozotocin-induced diabetes mellitus if administered for 
14 days at 600 mg/kg per day. Notably, blood glucose concentration decreased to 
physiological values [6, 7].
Blood glucose measurement evaluates current glucose concentration, which 
may depend on many factors (the intake and composition of food, physical activ-
ity and their intensity, the emotional state of the patient, and even the time of the 
day) [37]. Thus, blood glucose concentration may not reflect the actual degree of 
diabetes compensation, potentially resulting in medication under- or overdos-
ing. Therefore, today, the key indicator for treatment quality and risk of diabetes 
complications is the level of glycosylated hemoglobin (HbA1c) [37]. Notably, the 
non-alkaloid fraction of Galega officinalis extract normalizes HbA1c content under 
diabetes [6].
Sugar-reducing effect of non-alkaloid extract may be due to its complex com-
position [6, 36, 38]. Gas chromatography/mass spectrometry detected phytol as 
a component of non-alkaloid fraction of Galega officinalis extract. Phytol might 
contribute to the extract’s sugar-lowering effect, as it is known to lower insulin 
resistance and sensitivity of muscles to insulin and to reduce gluconeogenesis [39]. 
It has been shown that phytol can increase the expression of GLUT2 and glucokinase 
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genes through activation of RXR (retinoid X receptor) [39], which are otherwise 
downregulated under diabetes mellitus. Palmitic acid esters in the extract could 
also cause a dose-dependent decrease in blood plasma glucose in animals with 
experimental diabetes mellitus [40]. Furthermore, non-alkaloid fraction of Galega 
officinalis extract contains high levels of phytosterols (campesterol and stigmas-
terol) that, in addition to the ability to inhibit cholesterol adsorption, can reduce the 
level of glycosylated hemoglobin [41, 42].
Another notable biologically active substance from Galega officinalis is α-amyrin. 
It has a hypoglycemic action and can influence endocannabinoid system. Some 
ligands for cannabinoid CB1 receptors can directly bind and allosterically regulate 
Kir6.2/SUR1 K (ATP) channels, thereby controlling glucose-stimulated insulin 
release. In addition, α- and β-amyrin, due to their anti-inflammatory and antioxi-
dant properties, have a positive effect on the state of animals with streptozotocin 
diabetes [43].
It has been shown that quinazoline derivatives are capable to lower blood glucose 
level and body weight in obese animals [44]. Notably, the non-alkaloid fraction 
of Galega officinalis contains such substances (2-methyl-1,2,3a,4,5-hexahydro-
pyrrolo[1,2-a]quinazoline). These derivatives can increase the activity of AMPK, 
which results in increased glucose adsorption by muscle cells. It has been found 
that AMPK, in addition to regulating insulin release by pancreatic cells, inhibits the 
activity of acetyl-CoA-carboxylase and hydroxymethylglutaryl-CoA-reductase in 
fat cells, thereby inhibiting the biosynthesis of fatty acids and cholesterol [45].
High content of alpha-linolenic acid in Galega extract is also noteworthy. 
Omega-3 polyunsaturated fatty acids increase cell membrane fluidity, as well as 
the number of insulin receptors, the affinity of insulin to these receptors, and the 
number of type 4 glucose transporters; they also regulate the balance between pro- 
and antioxidants [46].
Based on the above statement, the sugar-lowering effect of the non-alkaloid 
fraction of Galega officinalis extract is likely due to the presence of phytol, ethyl 
ester of palmitic acid, phytosterols (campesterol and stigmasterol), and quinazoline 
derivatives, acting separately or synergistically [6].
3.2 Regulation of bone marrow cells proliferation by Galega officinalis
Many of diabetes complications are induced by the intensification of chronic 
inflammation and attenuation of the immune response. Leukocytes play major 
roles in inflammation and immune responses. Diabetes mellitus is accompanied by 
infectious and inflammatory processes, of which the most frequent are bacterial 
infections, which are accompanied by relapses and are difficult to treat. Changes 
in the proliferative activity and ratio of leukocytes and changes in their functional 
properties and activation of free radical oxidation are among probable causes of 
the propensity of patients with diabetes mellitus to infectious processes and their 
compromised immunological status [2].
Therefore, the measurement of the hypoglycemic effect is insufficient when 
testing the effectiveness of new antidiabetic agents. It is also necessary to evaluate 
the effect of potential hypoglycemic drugs on cells that are susceptible to metabolic 
changes in diabetes mellitus. Cells whose function is very significantly affected in 
the course of diabetes mellitus are white blood cells. High levels of glucose in the 
bloodstream cause inflammation, which primarily affects blood cells, in particular, 
leukocytes [47, 48].
In addition to a broad spectrum of substances with a hypoglycemic effect, the 
non-alkaloid fraction of Galega officinalis extract contains compounds with poten-
tial immunomodulatory effect. Galega officinalis normalizes differential count of 
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leukocytes in conditions of diabetes mellitus. In particular, it leads to an increase in 
the number of segmented and band neutrophils while overall lowering the number 
of lymphocytes to almost control values [49]. This indicates a normalization of the 
cell-mediated immune response, as one of the most important factors determining 
the activity of the immune system of an organism [49]. The normalization of the 
content of immunocompetent cells in blood after treatment of diabetic rats with 
Galega extract may be due to the influence of its biologically active substances on 
the proliferation of these cells.
The non-alkaloid fraction of Galega officinalis extract, as a source of biologically 
active substances with wide range of actions, significantly affects the proliferative 
activity of bone marrow cells in conditions of diabetes. In particular, in rats with 
streptozotocin-induced diabetes mellitus, the administration of Galega officinalis 
extract caused a significant decrease in leukocyte proliferation, which is otherwise 
very high under diabetes. However, a more detailed analysis showed that despite the 
overall growth of leukocyte proliferation under diabetes mellitus, the abundance 
of not all leukocyte types increases in the bone marrow [38]. In particular, under 
diabetes a reduction in the number of myeloblasts was shown, with the follow-
ing decrease of juvenile and staff neutrophils. By contrast, lymphoblast numbers 
increased. Interestingly, the number of lymphocytes in the bone marrow does not 
undergo significant changes, potentially because immature lymphocytes leave the 
bone marrow towards the bloodstream. Since the non-alkaloid fraction of Galega 
officinalis extract can regulate the proliferative activity of leukocyte precursors, it 
is able to influence on the content of different types of leukocytes. Galega officinalis 
extract administration causes a decline in lymphoblasts and segmented granulo-
cytes number, as well as an increase in numbers of lymphocytes and juvenile and 
staff granulocytes in the bone marrow of animals with diabetes mellitus. It has been 
proposed that this effect is due to the extract’s ability to regulate the tumor necrosis 
factor α (TNF-α) content, the amount of which significantly increases in diabetes 
mellitus [38].
Furthermore, the revealed influence of Galega officinalis extract on the pro-
liferative activity of leukocytes may relate to the presence of inositol [50], fatty 
acids [51, 52], especially α-linolenic acid [53–55], flavonoids [56–59], phytol [60], 
squalene [61], campesterol, and stigmasterol [62] as well as α-amyrin [38, 63].
3.3  Influence of Galega officinalis on functional state of leukocytes and their 
antioxidant-prooxidant balance
In diabetes, abnormal immune response manifests itself not only in the imbal-
ance in the process of leukocytes proliferation but also in the disruption of these 
cells’ functional activity. The main effectors of the inflammatory process are 
phagocytes [64]. The effectiveness of phagocytic response is largely determined by 
the nature and intensity of its initial stage—chemotaxis. However, because of its 
complexity, chemotaxis is one of the most vulnerable forms of neutrophil reactivity 
[65]. Therefore, the impairment of the functional capacity of phagocytes and other 
immunocytes is associated with the pathology of movement of these cells. The main 
mechanism that allows cell motility is actin polymerization, as it underlies in the 
formation of stress fibrils, lamellipodia, and filopodia [66].
In animals with diabetes, the non-alkaloid fraction of Galega officinalis extract 
causes a decrease in filamentous actin (F-actin) content; this can testify about the 
reduction in the formation of short pseudopodia on the leukocytes surface. These 
data indicate that the use of this extract reduces the change in the structural and 
functional properties of leukocytes, as well as decrease of leukocyte pre-activated 
state [67]. It is possible that the extract-induced decrease in actin polymerization 
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might regulate integrin-dependent interaction with vascular endothelium neces-
sary for leukocytes penetration through the blood vessel wall during inflammatory 
processes [68].
F-actin is represented by two pools: (1) long microfilaments (the constitutive 
fraction of cytoskeleton) located near the cell membrane and reaching towards the 
center of the cell and (2) short microfilaments located in the submembrane cortical 
network. Short filaments form a very dynamic fraction, since they are the first ones 
to initiate polymerization of actin membrane filaments at the time of leukocytes 
activation [69]. Along with F-actin high content in blood leukocytes in diabetes mel-
litus condition, the process of its polymerization is intensified with the formation of 
fraction of short actin filaments. The source of monomers for this polymerization is, 
to a large extent, products of cytoskeleton filaments depolymerization and, to a lesser 
extent, the cellular pool of monomeric actin. The increase in actin polymerization 
may be due to an increase in the phosphatidylinositol amount observed in diabetes 
mellitus [70]. These cellular messengers may act as inhibitors of phosphorylation of 
actin regulatory proteins that affect the redistribution of actin filaments and reduce 
the content of cytoskeleton actin filaments and proportionally increase the level of 
actin in the short filaments and monomers fractions [71].
The administration of the non-alkaloid fraction of Galega officinalis extract in 
leukocytes of animals with diabetes causes a pronounced depolymerization of short 
actin filaments. It is accompanied by the formation of actin monomers and their 
polymerization to a fraction of cytoskeleton filaments. Galega-induced changes in 
actin cytoskeleton organization of leukocytes under prolonged hyperglycemia are 
probably due to a decrease in the pre-activated state of leukocytes. This effect is 
mainly achieved by a decrease in the intensity of activation and translocation of the 
phosphatidylinositol-3′-kinase regulatory subunit in the cytoskeleton sites [68, 72]. 
Reduced amount of phosphatidylinositol-3′-kinase reaction products (phosphati-
dylinositol-3,4-diphosphate and phosphatidylinositol-1,3,4-triphosphate) in the cell 
results in association of the CAP protein with actin filaments, resulting in inhibition 
of actin polymerization [71].
As mentioned above, diabetes mellitus type 1 is characterized by pre-activated 
state of leukocytes. This state is associated with the structural and functional 
rearrangement of the receptor apparatus of these cells. Often, such alterations are 
realized through changes in the structure of surface glycoproteins that contain sialic 
acid [73]. In diabetes, N-acetyl-β,D-glucosamine residues are exposed to a greater 
degree compared to healthy subjects, while the exposure of sialic acids linked 
by α2→3 and α2→6-glycoside bonds to subterminal residues (β, D-galactose, or 
N-acetylgalactosamine) decreases. Quantitative redistribution of glycoconjugates 
in leukocyte membranes leads to the modification of signaling networks involved 
in intercellular interactions, as well as, to the disruption of the aggregation and 
adhesiveness of these cells [67]. Activation of membrane-bound neuraminidases 
in diabetes mellitus leads to a decrease in the total level of sialic acids on the cell 
membrane. Desialylation is accompanied by increased content of subterminal 
monosaccharide—β, D-galactose. Galactose-containing glycoproteins regulate 
leukocyte migration during the inflammatory process, accompanied by a dynamic 
rearrangement of actin cytoskeleton [74].
The non-alkaloid fraction of Galega officinalis extract normalizes the content 
and structures of the glycoproteins’ carbohydrate determinants that form leuko-
cytes’ glycocalyx.
Reduction in N-acetyl-β,D-glucosamine residue content upon Galega officinalis 
administration is important to restore normal leukocyte function. Normalized 
content of such receptors indicates completion of leukocytes pre-activation. It is 
known that N-acetyl-β,D-glucosamine-containing glycoproteins include a receptor 
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for N-formyl-methionyl-leucyl-phenylalanine, which stimulates a respiratory burst 
in neutrophil granulocytes by activating NADPH oxidase [75]. Also, N-acetyl-
β,D-glucosamine-containing glycoconjugates are involved in the adhesion of 
leukocytes to the endothelium during inflammation (through cell surface receptor 
macrophage-1 antigen or complement receptor 3, which mediates the interaction 
of neutrophil granulocytes with intercellular adhesion molecule-1) [75]. Thus, the 
normalization of the receptor content, which has N-acetyl-β,D-glucosamine in its 
structure, improves the cell’s response to extracellular stimuli with a corresponding 
restoration of the functional state of leukocytes.
Under streptozotocin-induced diabetes, the administration of the non-alkaloid 
fraction of Galega officinalis extract increases the content of α(2→3)-bond sialic 
acids to physiological levels. It is possible that this effect is due to the influence of 
the extract’s biologically active substances on the activity of enzymes involved in 
the cleavage or transfer of sialic acid residues (neuraminidase and trans-sialidase) 
[67, 76]. Glycoproteins that contain sialic acids are structural components of the 
leukocyte co-receptor complex CD3, which is present in all mature T-lymphocytes 
and is involved in their activation. It can be assumed that the use of Galega officina-
lis may lead to the restoration of the structure of carbohydrate determinants of the 
glycoprotein subunit CD3-γ or CD3-ε in the CD3 co-receptor. This in turn inhibits 
the attenuation of T cells maturation and, as a consequence, prevents the develop-
ment of the immune deficiency [77–79].
Consequently, receptor apparatus restoration by Galega officinalis extract deter-
mines the normalization of the cells’ response to extracellular signals, which ultimately 
leads to the reorganization of actin cytoskeleton elements. However, the leukocyte 
migration, and therefore the state of actin cytoskeleton, depends on the presence of 
adhesion molecules on leukocyte surface and on the presence of chemokines. One of 
these chemokines is TNF-α, a pleiotropic pro-inflammatory cytokine. Through the 
activation of various signaling cascades, it regulates cell proliferation, differentia-
tion, migration, and apoptosis [80, 81]. An increase in cytokine concentrations under 
diabetes [38, 67] stimulates leukocyte actin polymerization. TNF-α induces a brief 
increase in polymerized actin content by activating the Rho/ROCK (Rho-related 
protein kinase) signaling pathway in neutrophils. The activation of the Rho/ROCK sig-
naling pathway leads to the reorganization of the neutrophil cytoskeleton inducing the 
formation of stress fibers [82–84]. Galega extract decreases TNF-α content to physi-
ological levels. This effect is believed to be related to the presence of anti-inflammatory 
compounds, including flavonoids, methyl ester of linolenic acid, and α-amyrin [67].
Thus, the non-alkaloid fraction of Galega officinalis extract reduces leukocyte 
pre-activation by acting both on cellular receptor apparatus and on chemokine 
content in the medium. Reducing diabetes-induced leukocytes pre-activated 
state by Galega extract can significantly improve these cells’ functional state. One 
of the most important functional properties of neutrophils is their bactericidal 
action. It has been discovered that Galega officinalis greatly improved the microbe 
killing properties of cells. In particular, the non-alkaloid fraction of Galega offi-
cinalis extract causes a decrease in neutrophils myeloperoxidase content, whereas 
in conditions of diabetes, the content of this enzyme increases [38, 85]. Inhibition 
of myeloperoxidase production by neutrophils can play an important role in 
the prevention of vascular damage mediated by leukocytes. It is known that the 
excessive amount of myeloperoxidase can cause damage of the blood vessel walls 
by producing strong oxidants (HOCl and HOBr) or by nitration of the tyrosine 
residues in proteins. Altogether this can eventually result in cardiovascular  
diseases [86, 87]. It has been proposed that such inhibiting effect of Galega offici-
nalis extract may be due to the synergistic action of phytol, flavonoids, squalene, 
phytosterols, and amyrin [38].
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Along with the decrease in the content of myeloperoxidase, the non-alkaloid 
fraction of the Galega officinalis extract also reduces the content of cationic proteins 
[38] that mediate the killing of a variety of microorganisms through ion pore for-
mation in their membranes [88]. The latter effect is associated with the presence of 
flavonoids in the extract [38], because these compounds are able to inhibit cationic 
protein secretion [89].
Thus, the use of alkaloid-free Galega officinalis extract for the treatment of dia-
betes leads to the restoration of functional properties of leukocytes, as indicated by 
the reconstitution of glycoconjugate receptors on leukocyte membranes, normaliza-
tion of the ratio of polymerized and unpolymerized actin, as well as restoration of 
bactericidal properties of these cells.
Diabetes is accompanied by neutrophil malfunction caused, to a large extent, 
by the development of oxidative-nitrative stress [90]. Oxidative stress leads to the 
activation of immunocompetent blood cells and their aggregation and adhesion. 
Further, an increase in the synthesis of arachidonic acid and its metabolites, cyto-
kines, oxygen radicals, and secretion of lysosomal enzymes take place in activated 
leukocytes. Altogether, it ultimately leads to the development of atherosclerosis [91].
Due to the presence of a large number of biologically active substances with a 
potential antioxidant effect in the non-alkaloid fraction of Galega officinalis extract, 
it is possible to use this extract as a potential source of antioxidants. Indeed, under 
diabetes mellitus, the non-alkaloid fraction of Galega officinalis extract causes a 
significant reduction in ROS content in leukocytes, which is otherwise elevated in 
the pathology [92]. Reduction of ROS generation by leukocytes may be due to the 
influence of Galega extract on the activity of the three main enzymatic systems 
responsible for generation ROS: membrane-bound NADPH oxidase, peroxidase—
myeloperoxidase in neutrophils and eosinophil peroxidase in eosinophils, as well 
as NO synthase. Indeed, a decrease in the content of myeloperoxidase in polymor-
phonuclear leukocytes [38] and reduction of the total activity of NO synthase was 
confirmed [93]. In addition to decreasing the activity of ROS synthesis enzymatic 
systems, the non-alkaloid extract of Galega officinalis significantly reduces the 
processes of protein and lipid oxidative modification. This effect is due to a decrease 
in total ROS content and NO stable metabolites (nitrite and nitrate anions), with 
the corresponding termination of biosubstrate oxidation by free radicals. Reduction 
of oxidative modified proteins and lipids stops the chain reaction of oxidative-nitric 
stress in conditions of diabetes and confirms the antioxidant effect of the Galega 
officinalis extract [38, 93].
The negative action of ROS in the body is counterbalanced by an antioxidant 
system, whose functioning is aimed at neutralizing free radicals, as well as repairing 
damages caused by them [94]. However, in conditions of oxidative-nitrative stress, 
which is largely activated during diabetes, antioxidant system of blood cells cannot 
fully implement its protective and adaptive mechanisms. The abnormal function-
ing of the immune system is evident from a decrease in the superoxide dismutase, 
catalase, and glutathione peroxidase activity in leukocytes. Under diabetes, the 
non-alkaloid fraction of Galega officinalis extract has a protective effect on the 
key components of the antioxidant defense system, causing a significant increase 
in superoxide dismutase and catalase activities [92]. Restoration of antioxidant 
defense enzymes activity by biologically active substances may be caused by inhibi-
tion of the glycosylation of these enzymes, mediated by the hypoglycemic effect 
of the extract. The increased activity of the antioxidant enzymes is in line with the 
observed suppression of the formation of oxygen and nitrogen reactive forms, as 
well as protein and lipid oxidation [38, 93].
The protective effect of the non-alkaloid fraction of Galega officinalis extract 
on blood cells can be explained by its ability to regulate the prooxidant-antioxidant 
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balance by means of scavenging free radicals and preventing the inhibition of key 
components of enzymatic antioxidant system. The main active ingredients of the 
extract that exhibit antioxidant properties are phytol, showing its properties due 
to its hydroxyl group [95] and, flavonoids, serving as a traps for electrons and free 
radicals and thus suppressing the chain reactions of free radical biosubstrate oxida-
tion [38, 89, 93]. Also, α-amyrin [43] and α-linoleic acid [46] possess pronounced 
antioxidant activities.
3.4  Galega officinalis prevents leukocytes apoptosis induced by diabetes 
mellitus
The development of diabetes mellitus is accompanied by a significant intensifi-
cation of oxidative-nitrative stress, resulting in the formation of substances with a 
strong proapoptotic effect. Especially sensitive to such substances are blood cells, 
including leukocytes. The response of immune cells to antigenic stimuli, as well as 
the nature, dynamics, and duration of the immune response and immunological 
tolerance formation are partially regulated through programmed cell death [96]. 
The non-alkaloid fraction of Galega officinalis extract causes inhibition of DNA 
fragmentation, which is a biochemical marker of apoptosis [97].
Other studies have shown that the use of the non-alkaloid fraction of Galega 
officinalis extract in animals with diabetes leads to a reduction of lymphocytes with 
features of apoptosis, in particular to reduction of phosphatidylserine (PS) residue 
translocation from the inner to the outer side of the membrane [38]. Changes in the 
intensity of lymphocyte apoptosis may be due to the effect of extract on the content 
of TNF-α. It is known that TNF-α reacts with the so-called death receptors and 
activates procaspases that trigger the apoptotic cascade [98]. Thus, a decrease in 
TNF-α content might suggest that one of the mechanisms by which Galega officina-
lis inhibits apoptosis in immunocompetent cells is by suppressing the extrinsic, or 
death receptor, apoptosis pathway [38].
Another evidence for the activation of the extrinsic apoptosis pathway under 
diabetes is exposure on leukocytes’ immature membrane epitopes with modified 
sialic acid content. It takes place in response to the loss of surface membrane during 
cytoplasmic membrane blebbing [99]. The administration of Galega officinalis 
extract to diabetic animals causes an increase in the content of sialic acid residues 
linked by α(2→3) and α(2→6) glycosidic bonds with the subterminal surface 
glycoconjugate residues of rat leukocytes [75].
On the other hand, it has been found that Galega officinalis is able to regulate 
the processes of the intrinsic (mitochondrial) pathway of apoptosis. In particular, 
it reduces the levels of the apoptosis regulatory proteins p53 and Bcl-2 [75, 97]. It 
is known that cell damage results in p53 translocation from the cytoplasm into the 
mitochondria [100]. In the mitochondria this protein undergoes rapid enzymatic 
de-ubiquitination that yields an active form which interacts with BH4 domain of 
antiapoptotic proteins Bcl-XL and Bcl-2 [100]. Binding to antiapoptotic proteins 
induces the release and activation of proapoptotic proteins Bax and Bid. Such 
interactions lead to the release of cytochrome c and induction of apoptosis [101, 
102]. At the same time, Galega officinalis in leukocytes regulates the content of 
Bcl-2, a protein that inhibits both p53-dependent and p53-independent pathways 
of apoptosis. Reduction of this protein content promotes the formation of ion 
channels in mitochondria membrane, thus stabilizing the mitochondrial cyto-
chrome c oxidase and regulating the activation of proteins that are involved in 
apoptosis [75, 97].
Another significant confirmation of Galega officinalis antiapoptotic action is the 
reduction of the content of PARylated proteins in leukocytes under diabetes [75]. 
Metformin
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This indicates a decrease in DNA damage with the corresponding inhibition of DNA 
repair complex (base excision repair in response to single-stranded DNA breaks and 
nucleotide excision repair), which includes poly (ADP-ribose) polymerase enzyme 
[103]. Thus, Galega-induced decrease in protein PARylation could stem from inhibi-
tion of poly (ADP-ribose) polymerase activity, which can be assumed to prevent 
ribosylation of a number of proteins, including glyceraldehyde-3-phosphate 
dehydrogenase. In the presence of excess glucose, this results in inactivation of the 
polyol and hexosamine pathways, thereby preventing the accumulation of products 
and precursors of nonenzymatic glycosylation and activation of protein kinase 
C. As the final result, this leads to the inhibition of oxidative-nitric stress manifesta-
tions and prevents the occurrence of chronic diabetic lesions [75].
The established antiapoptotic effect of Galega officinalis extract is mediated by 
sugar-reducing, antioxidant, and anti-inflammatory properties of its components. 
In particular, the composition of the extract revealed a number of compounds that 
have potentially hypoglycemic (phytol, ethyl ester of palmitic acid, campesterol, 
stigmasterol, and quinazoline derivatives), antioxidant (phytol, flavonoids, vitamin 
E), and anti-inflammatory (flavonoids, methyl ester of linolenic acid, α-amyrin) 
effects [38].
4. Conclusions
Metformin has become widely used in the treatment of diabetes mellitus type 
2 over the last period of time. This is due to the fact that metformin, along with its 
hypoglycemic effect, has the potential to modulate the functioning of immuno-
competent blood cells. Metformin transiently inhibits NADH:ubiquinone oxidore-
ductase of the mitochondrial electron transport chain. This inhibition leads to the 
activation of the energy sensor 5′-AMP-activated protein kinase. The activation of 
this enzyme results in a whole range of metabolic changes in the immunocompetent 
cells. Metformin is able to regulate the processes of bone marrow cell proliferation, 
affect the functional activity, and regulate the apoptosis processes of immunocom-
petent cells.
To date, practically all mechanisms of therapeutic influence of metformin are 
well described. Instead, the plant from which this biguanide was first obtained 
somewhat become underestimated. Under diabetes mellitus type 1, the non-alka-
loid fraction of Galega officinalis possesses pronounced hypoglycemic effect. The 
non-alkaloid fraction of Galega officinalis normalizes the leukocyte proliferation 
processes by restoring the neutrophils bone marrow pool and reducing the lympho-
blasts number. This extract affects the functional state of immunocompetent cells in 
blood, leading to quantitative redistribution and structural alterations of carbohy-
drate determinants in leukocyte membranes, reorganization of actin cytoskeleton, 
as well as affecting the bactericidal function of neutrophils. Furthermore, non-
alkaloid fraction of Galega officinalis predetermines the suppression of leukocyte to 
genetically programmed death. The multifactorial effect of Galega officinalis extract 
under diabetes may be, on the one hand, due to its potent hypoglycemic effect, and, 
on the other hand, due to its ability to regulate the prooxidant-antioxidant balance 
by scavenging free radicals and preventing the inhibition of key enzymatic compo-
nents of the antioxidant defense system.
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